Phase III RCT in 644 patients with untreated advanced triple-negative breast cancer not suited to immunotherapy: datopotamab deruxtecan vs chemotherapy improved median PFS (10.8 vs 5.6 months; HR 0.57) and OS (23.7 vs 18.7 months; HR 0.79).
RCTn = 644 patients
Dent et al. Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial